Henri Termeer, the former CEO of Cambridge, MA-based Genzyme, has joined the board of Verastem, a startup seeking to develop treatments against cancer stem cells. Verastem, co-founded by MIT biologists Robert Weinberg and Eric Lander, raised $16 million last November, in a round that included Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners, and MPM Capital. “We believe that Henri’s extensive experience and expertise, gained from building Genzyme into a leading global biotechnology company, will serve as an invaluable asset for Verastem,” said chairman Christoph Westphal, in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
